Replies to post #285984 on Over The Counter Stocks

[Screech691]

$IMLFF After making significant progress in 2016, the company is finalizing the transdermal formulation for its Epidermolysis Bullosa (EB) therapy and plans to complete toxicology testing in 2017. The team plans to begin clinical trials in 2018 and will seek an expedited review process with regulatory authorities, including the U.S. FDA, to minimize this product's time-to-market.